Sanofi climbs 19 places to third on the 2026 Global Pharmaceutical Innovation Index, marking the largest rise within this year’s Top 10, while falling five places to 17th on the Invention Index. Its performance reflects a company that has evolved into a launch- and readout-driven R&D organization. Management framed 2025 as a year of profitable growth, multiple regulatory approvals, positive Phase 3 readouts and successful launches, with both sales and earnings increasing alongside continued investment in R&D.

Dupixent (dupilumab) generated full-year global sales of $18.7 billion, up 25% at constant exchange rates, and continues to expand across indications. The FDA and EC have approved Dupixent in chronic spontaneous urticaria, marking the first new targeted therapy in the indication in over a decade. It has also received FDA approval in bullous pemphigoid and became the first biologic approved for COPD in Japan. Pediatric asthma data further demonstrated reductions in exacerbations versus placebo, while a Phase 4 head-to-head study showed Dupixent outperforming Xolair (omalizumab) across all primary and secondary endpoints in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma.

Regulatory momentum across the broader portfolio remains strong. Sarclisa (isatuximab) has secured approvals across the EU, Japan and China in newly diagnosed multiple myeloma, becoming the first anti-CD38 therapy approved with VRd (Velcade, Revlimid, dexamethasone) for both transplant-eligible and transplant-ineligible patients in the EU. Qfitlia (fitusiran) received FDA approval as the first antithrombin-lowering therapy for haemophilia A and B, Wayrilz (rilzabrutinib) was approved in the US and EU for immune thrombocytopenia, and Tzield (teplizumab) received a positive CHMP opinion as a disease-modifying therapy in stage 2 type 1 diabetes.